A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects
Status:
Completed
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
Debio 1450 is metabolised mainly by CYP3A4, therefore inhibitors of CYP3A4 have the potential
to raise Debio 1450 plasma concentrations. Hence, it is important to determine the effect of
CYP3A4 inhibition by itraconazole on the Pharmacokinetics of Debio 1450.